Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Adhansia XR in Children
NCT04987762Phase 4Terminated
- Sponsor
- Purdue Pharma
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Adhansia XR in attention deficit hyperactivity disorder (ADHD), sponsored by Purdue Pharma. Primary endpoint: The Number of Participants With Adverse Events as a Measure of Safety up to 9 months. Started Aug 2021; status: terminated.
02
Drugs
Adhansia XR
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04987762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987762.